Rewalk Robotics

A U.S. Court of Appeals for the First Circuit has dismissed a 2017 class action lawsuit filed against ReWalk Robotics of Marlborough on Tuesday, according to a press release from the medical device manufacturer. 

ReWalk Robotics in Marlborough reported a 90% increase in revenue in the company’s second quarter, compared to the same time period in the year prior, according to a quarterly earnings report released Wednesday.

ReWalk Robotics in Marlborough announced on Wednesday it has entered into definitive agreements with several institutional investors providing for the issuance of nearly 5 million of the company’s ordinary shares, at a purchase price of $1.8225.

Marlborough medical device manufacturer ReWalk Robotics on Thursday reported 50% less revenue in the first quarter, compared to the same time period in 2019, the company announced on Thursday.

ReWalk Robotics, a Marlborough maker of wearable robotic exoskeletons for those with lower limb disabilities, is looking to raise money for sales, marketing and research and development.

ReWalk Robotics stock hit an historic low on Wednesday morning of $2.19 per share after the company’s reported declining revenues and sales in its third quarter.

Despite recent U.S. and European clearances for exoskeleton devices for stroke patients, ReWalk Robotics reported a softer second quarter than expected, sending the company’s stock down nearly 10% on Thursday morning. 

ReWalk Robotics hopes to eventually reach profitability after the U.S. Food & Drug Administration last week approved the ReStore, an exoskeleton system designed to help stroke patients rehab and eventually walk again.

ReWalk Robotics on Monday announced it will raise another $5 million from a sale of more than 833,000 shares to institutional investors on the heels of a key regulatory approval.

Marlborough biotech manufacturer ReWalk Robotics’ stock skyrocketed Wednesday, rising more than 180% after the company announced FDA clearance of one of ReWalk's main products.